GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medicenna Therapeutics Corp (TSX:MDNA) » Definitions » Accounts Receivable

Medicenna Therapeutics (TSX:MDNA) Accounts Receivable : C$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Medicenna Therapeutics Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Medicenna Therapeutics's accounts receivables for the quarter that ended in Dec. 2023 was C$0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Medicenna Therapeutics's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was C$0.25.


Medicenna Therapeutics Accounts Receivable Historical Data

The historical data trend for Medicenna Therapeutics's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicenna Therapeutics Accounts Receivable Chart

Medicenna Therapeutics Annual Data
Trend Dec15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only - - - - -

Medicenna Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Medicenna Therapeutics Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Medicenna Therapeutics Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Medicenna Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Medicenna Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Medicenna Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(21.758+0.75 * 0+0.5 * 0-4.639
-0-0)/69.6375
=0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Medicenna Therapeutics Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Medicenna Therapeutics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Medicenna Therapeutics (TSX:MDNA) Business Description

Traded in Other Exchanges
Address
2 Bloor Street W., 7th Floor, Toronto, ON, CAN, M4W 3E2
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.

Medicenna Therapeutics (TSX:MDNA) Headlines

No Headlines